CLOs on the Move

Oxford Medical Simulation

www.oxfordmedicalsimulation.com

 
Oxford Medical Simulation delivers virtual reality medical simulation - training healthcare professionals to provide consistently world-class patient management without risking lives. Medical simulation has become central to medical training and is highly effective. However, it is expensive, low throughput and not widely accessible. Healthcare workers therefore struggle to get the training they need to deliver optimal patient care. We remove these barriers by offering virtual reality training scenarios. These provide a completely safe, controlled-stress learning environment for all healthcare professionals. The focus is on clinical decision-making under pressure, crisis resource management, team interaction and patient engagement. Our fast-paced, repeatable, real-life ...
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Xperiome

Xperiome is a global healthtech company that helps pharma get to know rare disease patients and their conditions faster by delivering deep insights into the patient experience. We have created Raremark as the place for the lived experience of rare disease. Raremark supports every stage of a patient`s health odyssey: a community to crowdsource wisdom, a library to catalog the lived experience, and a matching engine to find research opportunities. This data-driven knowledge bank of the rare experience allows us to match research-ready members to clinical and real-world studies, faster and smarter than ever before.

Cellanyx

Cellanyx has developed proprietary live tumor cell phenotypic biomarker tests to improve cancer risk-stratification and allow informed clinical decision making. The Companys unique approach provides quantitative and actionable information based on analysis of thousands of live tumor cells. The Companys tests employ a microfluidic platform combined with machine vision and machine learning approaches to analyze phenotypic morphological, biochemical and biophysical markers. Cellanyx has demonstrated initial clinical proof-of-concept with its lead phenotypic test in prostate cancer. The initial clinical proof-of-concept study was conducted to demonstrate improved risk stratification in men with low and intermediate Gleason grade (6 and 7) disease and reduce the number of repeat biopsies. Furthermore, analysis of field samples (away from the suspicious core) demonstrated the potential value of Cellanyx phenotypic test as it was able to analyze the tumor microenvironment conditions and predict expected adverse pathology from samples that were not taken from the suspicious core. These new findings from the Cellanyx prostate test are transformative as it will reduce the errors in diagnosing cancers early due to sampling heterogeneity of prostate biopsies.

WellCheck Inc

WellCheck Inc is a Oakland, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

We Level Up

We Level Up Treatment Centers is a network of top-rated, accredited detox centers, addiction rehab, and mental health dual diagnosis behavioral health centers. They offer comprehensive programs of intense integrated psychotherapy, peer support groups, ...

Clinical Resources Group

Clinical Resources Group is a Scottsdale, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.